Pfizer appointed Cyrus Taraporevala to its board of directors on Monday. 

In addition to serving on the broader board, Taraporevala will also serve on the drugmaker’s audit committee and compensation committee. 

Taraporevala has held numerous leadership roles throughout his lengthy career in asset management. 

Most recently, he served as president and CEO at State Street Global Advisors, a major asset manager, from 2017 until his retirement in 2022. 

Prior to that, he spent more than three decades in leadership across numerous companies, including Fidelity, BNY Mellon, Legg Mason, Citigroup as well as McKinsey & Co. 

During this time, he specialized in driving organic and inorganic growth, transformations and turnarounds.

He was also a founding member of the New York Stock Exchange Board Advisory Council, which works to connect diverse job candidates with companies seeking new directors in an effort to address the growing need for more inclusion at the leadership level. 

The pharma giant highlighted his wealth of business experience as one of the many reasons for his appointment.

“We are pleased to welcome Cyrus Taraporevala to Pfizer’s board of directors,” Pfizer CEO Albert Bourla said in a statement. “He brings vast experience in investment management, financial markets plus leadership and global operations more broadly that will be an asset to Pfizer and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.”

In his role on the audit committee, he will be joining four other independent financial experts, including the chair of the committee, Suzanne Nora Johnson. In this body, they will review the company’s financial operations with management, the internal auditor and independent auditors. 

Meanwhile on the compensation committee, he will be joining three other members, including the chair of the committee, James C. Smith, as they work to establish goals and objectives for elected officers. 

In addition to Pfizer, Taraporevala serves on the board of energy giant Shell and Bridgepoint Group, an investment management group.

He also serves on two nonprofit boards: The Trustees of Reservations, an organization dedicated to land conservation and historic preservation, as well as public media company GBH. 

His appointment to Pfizer’s board comes weeks before the drugmaker is slated to release its latest earnings report on July 30.